Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126247831 | 12624783 | 1 | I | 20160722 | 20160805 | 20160805 | EXP | US-SUN PHARMACEUTICAL INDUSTRIES LTD-2016US-120956 | RANBAXY | 48.00 | YR | M | Y | 0.00000 | 20160805 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126247831 | 12624783 | 1 | PS | TEMOZOLOMIDE. | TEMOZOLOMIDE | 1 | Unknown | 170 MG/M^2 (DAYS 10-14 EVERY 28 DAYS) | U | 201742 | |||||||||
126247831 | 12624783 | 2 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | 700 MG/M2, BID (DAYS 1-14 EVERY 28 DAYS) | U | 0 | 700 | MG/M**2 | Q12H |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126247831 | 12624783 | 1 | Neuroendocrine tumour |
126247831 | 12624783 | 2 | Neuroendocrine tumour |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126247831 | 12624783 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126247831 | 12624783 | Fatigue | |
126247831 | 12624783 | Nausea | |
126247831 | 12624783 | Neoplasm progression | |
126247831 | 12624783 | Therapeutic response decreased | |
126247831 | 12624783 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |